December 23, 2024 Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease Read More
November 14, 2024 Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update Read More
October 23, 2024 Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 Read More
October 15, 2024 Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Read More
October 9, 2024 Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference Read More
September 30, 2024 Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers Read More
September 26, 2024 Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease Read More
September 19, 2024 Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024 Read More
September 3, 2024 Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference Read More
August 29, 2024 Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease Read More
August 8, 2024 Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update Read More
July 9, 2024 Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease Read More
June 27, 2024 Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease Read More
June 25, 2024 Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference Read More
May 30, 2024 Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024 Read More
May 14, 2024 Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update Read More
April 24, 2024 Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease Read More
April 8, 2024 Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer Read More
April 1, 2024 Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer Read More
March 26, 2024 Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update Read More
March 5, 2024 Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease Read More
